Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 44, Issue 11-12, Pages 1199-1212
Publisher
Wiley
Online
2016-10-13
DOI
10.1111/apt.13813
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
- (2016) Aurelien Amiot et al. Clinical Gastroenterology and Hepatology
- Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy
- (2016) Uri Kopylov et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
- (2015) Anika Fischer et al. GUT
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
- (2015) Edward Shelton et al. INFLAMMATORY BOWEL DISEASES
- Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohnʼs Disease
- (2015) Gilles Boschetti et al. INFLAMMATORY BOWEL DISEASES
- Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment
- (2015) Johannan F. Brandse et al. Journal of Crohns & Colitis
- Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice
- (2015) Emily E. Vivio et al. Journal of Crohns & Colitis
- Vedolizumab for the treatment of ulcerative colitis
- (2015) Andreas Stallmach et al. Expert Review of Gastroenterology & Hepatology
- Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?
- (2014) Shomron Ben-Horin DIGESTIVE DISEASES
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
- (2012) W. Reinisch et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
- (2011) Matthias Jürgens et al. Clinical Gastroenterology and Hepatology
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis
- (2011) M. De Vos et al. Journal of Crohns & Colitis
- Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
- (2010) N. Gies et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab
- (2010) M. Papoutsaki et al. DERMATOLOGY
- Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
- (2010) Matthieu Allez et al. Journal of Crohns & Colitis
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
- (2008) James D. Lewis et al. INFLAMMATORY BOWEL DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started